MMR vaccine - How effective and how safe?

Drug and Therapeutics Bulletin

Volumn 41, Issue 4, 2003, Pages 25-29

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MMR II; MUMPS VACCINE; VIRUS RNA;

ARTHRALGIA; ASEPTIC MENINGITIS; AUTISM; CHILD; COMMON COLD; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEBRILE CONVULSION; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; INCIDENCE; IRRITABILITY; MEASLES; MONOTHERAPY; MOOD DISORDER; MUMPS; PAROTID GLAND DISEASE; POSTMARKETING SURVEILLANCE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RUBELLA; SUBACUTE SCLEROSING PANENCEPHALITIS; UNITED KINGDOM; VOMITING;

EID: 0037397936     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2003.41425     Document Type: Review

References (44)

1. Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). Immunisation against infectious disease. London: HMSO, 1996.
2. Public Health Laboratory Service, 2003. Vaccines and vaccine safety [online]. Available: http://www.phls.co.uk/topics_az/vaccination/vacc_menu.htm [Accessed 19 March 2003].
3. Wakefield AJ et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
4. Ramsay ME et al. Parental confidence in measles, mumps and rubella vaccine: evidence from vaccine coverage and attitudinal surveys. Br J Gen Pract 2002; 52: 912-6.
5. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. Measles immunisation in HIV-infected children. Pediatrics 1999; 103: 1057-60.
6. Royal College of Paediatrics and Child Health. Immunisation of the immunocompromised child. Best practice statement. February 2002.
7. Khakoo GA, Lack G. Recommendations for using MMR vaccine in children allergic to eggs. BMJ 2000; 320: 929-32.
8. Lerman SJ et al. Clinical and serological evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981; 68: 18-22.
9. Robertson CM et al. Serological evaluation of a measles, mumps, and rubella vaccine. Arch Dis Child 1988; 63: 612-6.
10. Edees S et al. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991; 105: 91-7.
11. Peltola H et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331: 1397-402.
12. Hersh BS et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119: 187-93.
13. Vitek CR et al. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr Infect Dis J 1999; 18: 620-3.
14. Salmon DA et al. Health consequences of religious and philosophical exemptions from immunization laws. Individual and societal risk of measles. JAMA 1999; 282: 47-53.
15. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986; 1: 939-42.
16. Virtanen M et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination [online]. Pediatrics 2000; 106: e62. Available: http://www.pediatrics.org/cgi/content/full/106/5/e62 [Accessed 19 March 2003].
17. Farrington P et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-9.
18. Barlow WE et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345: 656-61.
19. Makela A et al. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110: 957-63.
20. White CC et al. Benefits, risks and costs of immunization for measles, mumps, and rubella. Am J Public Health 1985; 75: 739-44.
21. Miller E et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341: 979-82.
22. Jin L et al. Characterization of measles virus strains causing SSPE: a study of 11 cases. J Neurovirol 2002; 8: 335-44.
23. Black C et al. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003; 55: 107-11.
24. Benjamin CM et al. Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine. BMJ 1992; 304: 1075-8.
25. Filipek PA et al. Practice parameter: screening and diagnosis of autism. Neurology 2000; 55: 468-79.
26. Medical Research Council. Review of autism research. Epidemiology and causes. December 2001. London: MRC, 2001.
27. Wakefield AJ et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000; 95: 2285-95.
28. Furlano RI et al. Colonic CD8 and γd T-cell infiltration with epithelial damage in children with autism. J Pediatr 2001; 138: 366-72.
29. Wakefield AJ. Autism - why the increased rates? A one year update. Testimony to the Congressional Oversight on Government Reform. Washington. April 2001.
30. Wakefield AJ. Vaccines and autism. Enterocolitis, autism and measles virus. Molec Psychiatr 2002; 7: S44-6.
31. Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug React Toxicol Rev 2000; 19: 265-83.
32. Uhlmann V et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. J Clin Pathol Mol Pathol 2002; 55: 84-90.
33. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism [online]. Pediatrics 2001;108: e58. Available: http://www.pediatrics.org/cgi/content/full/108/4/e58 [Accessed 19 March 2003].
34. Taylor B et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-9.
35. Farrington CP et al. MMR and autism: further evidence against a causal association. Vaccine 2001; 19: 3632-5.
36. Taylor B et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393-6.
37. Kaye JA et al. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460-3.
38. Black C et al. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002; 325: 419-21.
39. DeWilde S et al. Do children who become autistic consult more often after MMR vaccination? Br J Gen Pract 2001; 51: 226-7.
40. Gillberg C, Heijbel H. MMR and autism. Autism 1998; 2: 423-4.
41. Dales L et al. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285: 1183-5.
42. Madsen KM et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347: 1477-82.
43. Mayor S. MMR advocate wants to give parents the choice. BMJ 2002; 324: 1118.
44. Jarmulowicz M. Single measles vaccine should be allowed. BMJ 2002; 324: 734.